PAR-25-145-Full-Announcement.html

This document is a Funding Opportunity Announcement (FOA) for the "Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)" grant opportunity, solicitation number PAR-25-145.

The purpose of this FOA is to support collaborative research projects that identify the mechanisms of, clinically characterize, and develop interventions to prevent or minimize long-term adverse effects from cancer therapies. Eligible applicants include a wide range of organizations, including small businesses, nonprofits, higher education institutions, and state/local governments. The grant is funded by the National Institutes of Health under the Cancer Cause and Prevention Research program (CFDA 93.393). The FOA seeks basic, translational, and clinical research projects that focus on developing biomarkers, imaging, patient-reported outcomes, or combined approaches to evaluate interventions for preventing or reducing specific adverse sequelae of cancer therapies.